Physician profile
Curtis E Lake
NPI 1750892675
$2,266.04
in general payments reported to CMS, 2019-2025
24 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $215 · 2023: $257 · 2024: $736 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.60 | 2021-2025 | |
| Ucb, INC. | $321.01 | 2023-2025 | Briviact, Rystiggo, Zilbrysq |
| Medtronic, INC. | $206.05 | 2021-2022 | |
| Pfizer INC. | $181.59 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $133.72 | 2023-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $132.82 | 2021-2025 | |
| Eisai INC. | $86.59 | 2024-2025 | |
| Lilly USA, LLC | $72.79 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $72.32 | 2022-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $70.21 | 2022 | |
| Argenx US, INC. | $55.36 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $54.19 | 2024-2025 | Radicava |
| Sk Life Science, INC. | $43.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.97 | 2023-2024 | Andexxa |
| Amylyx Pharmaceuticals, INC. | $31.98 | 2023 | Relyvrio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.83 | 2023-2025 | Austedo Xr, Austedo Xr |
| Kyowa Kirin, INC. | $22.17 | 2025 | |
| Aucta Pharmaceuticals, INC. | $22.07 | 2025 | Motpoly Xr |
| Amgen INC. | $21.76 | 2025 | Uplizna |
| Acadia Pharmaceuticals INC | $17.79 | 2025 | Daybue |
| Jazz Pharmaceuticals INC. | $17.01 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.96 | 2022 | |
| Merz Pharmaceuticals, LLC | $13.34 | 2023 | Xeomin |
| Janssen Pharmaceuticals, INC | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.